Original Medicaid Favors Brand Insulin; Managed Care Favors Generics

Inside Heath Policy highlights new study showing how states continue to use branded insulin despite cheaper and equally effective options. Jeff Myers, Catalyst Senior VP of Market Access and Reimbursement Strategies, explains how the Medicaid Drug Rebate Program encourages fee for service Medicaid program to wastefully spend taxpayer dollars, while managed care programs drive overall costs down.

https://insidehealthpolicy.com/share/113238

2020-02-20T21:25:12+00:00